Sun’s deuruxolitinib and Novo Nordisk’s insulin icodec stand out as new molecular entities among the small cluster of US FDA user fee goal dates in July.

An analysis of new ADCs in Phase III studies shows the difficulties, and possible rewards, of developing these drugs.

The protein-degrader company has updated results in heavily pre-treated CLL and NHL patients, keeping it competitive with rival BeiGene.

Signs are that the rate of sales growth for orphan drugs is slowing but that does not mean that they have had their day. Far from it, finds a new report from Evaluate.